

Exhibit D

Confidential - Subject to Stipulation and Order of Confidentiality

1 - - -
2 :SUPERIOR COURT OF
:NEW JERSEY
3 IN RE: :LAW DIVISION -
PELVIC MESH/GYNECARE :ATLANTIC COUNTY
4 LITIGATION :
:MASTER CASE 6341-10
5 :
:CASE NO. 291 CT

6
7 CONFIDENTIAL-SUBJECT TO STIPULATION AND ORDER OF
8 CONFIDENTIALITY

9 March 14, 2012

10
11 Transcript of the continued
12 deposition of DAVID B. ROBINSON, MD, called for
13 Videotaped Examination in the above-captioned
14 matter, said deposition taken pursuant to Superior
15 Court Rules of Practice and Procedure by and before
16 Ann Marie Mitchell, a Federally Approved Certified
17 Realtime Reporter, Registered Diplomat Reporter,
18 Certified Court Reporter, and Notary Public for the
19 State of New Jersey, at the offices of Riker Danzig
20 Scherer Hyland & Perretti LLP, Headquarters Plaza,
21 One Speedwell Avenue, Morristown, New Jersey,
22 commencing at 9:35 a.m.

23 - - -
GOLKOW TECHNOLOGIES, INC.
24 877.370.3377 ph | 917.951.5672 fax
deps@golkow.com

Confidential - Subject to Stipulation and Order of Confidentiality

1 director in Ethicon, you did not expect physicians
2 to rely upon the IFU for the Prolift® as an accurate
3 disclosure of the risks associated with the Prolift®
4 system?

5 MR. GAGE: Objection.

6 THE WITNESS: No. I think what I
7 said is I didn't -- they shouldn't depend on it as
8 the sole source of their information regarding the
9 Prolift® system.

10 BY MR. SLATER:

11 Q. My question is this: Did you expect
12 surgeons who were considering using the Prolift® to
13 rely upon the Prolift® IFU to accurately disclose
14 the risks associated with the use of the Prolift®
15 system?

16 MR. GAGE: Objection.

17 THE WITNESS: We should accurately
18 represent what we knew to be risks at the time, yes.

19 BY MR. SLATER:

20 Q. You knew that was required by federal
21 law. Right?

22 MR. GAGE: Objection.

23 BY MR. SLATER:

24 Q. By the FDA. Right?

25 MR. GAGE: Objection.

Confidential - Subject to Stipulation and Order of Confidentiality

1 THE WITNESS: Actually, I don't know
2 whether the FDA -- that is a regulatory decision.

3 BY MR. SLATER:

4 Q. And you felt that was your obligation
5 to physicians so they would know what the potential
6 adverse reactions were if they used that product.
7 Right?

8 MR. GAGE: Objection.

9 THE WITNESS: To the best of our
10 knowledge at the time, yes.

11 BY MR. SLATER:

12 Q. And if Ethicon had knowledge of an
13 adverse reaction and did not include it in the
14 Prolift® IFU, then the IFU would be deficient to
15 that extent. Right?

16 MR. GAGE: Objection.

17 THE WITNESS: No, that's not true.

18 BY MR. SLATER:

19 Q. Okay.

20 A. Because --

21 Q. So let me understand this.

22 MR. GAGE: The witness would like to
23 finish his answer.

24 MR. SLATER: He just said no. That's
25 all I was asking.

Confidential - Subject to Stipulation and Order of Confidentiality

1 Q. Well, I'm asking you, based on your
2 participation in the process at Ethicon, would that
3 be incorrect?

4 MR. GAGE: Objection.

5 THE WITNESS: I don't remember ever
6 being asked to give the -- a final decision about
7 adverse events being put in an IFU.

8 BY MR. SLATER:

9 Q. Let me understand this. Ethicon
10 understood it was expected to put all of the adverse
11 events into the IFU. However, if Ethicon failed to
12 list -- I'm going to ask the question differently.

13 If Ethicon determined an adverse
14 reaction to be material, meaning it doesn't just
15 happen, you know, so infrequently that you don't
16 have to consider it but it happens enough that you
17 can actually put a percentage on it --

18 A. Well --

19 MR. GAGE: Let him finish his
20 question.

21 BY MR. SLATER:

22 Q. Let me ask you this.

23 How would you define a complication
24 to be material enough that it would need to be
25 listed in the IFU? How did you define that as

Confidential - Subject to Stipulation and Order of Confidentiality

1 medical director?

2 A. Well, it would either need to have a
3 frequency or a severity that had some implication
4 for a risk/benefit ratio.

5 Q. Okay.

6 If a complication met that standard,
7 it needed to be called out in the IFU. Right?

8 A. Yes.

9 Q. And if it was not -- rephrase.

10 And if a complication that met that
11 standard was not included in the IFU, the IFU would
12 be deficient by definition. Correct?

13 MR. GAGE: Objection.

14 THE WITNESS: I think it has to be
15 based on the information you have at the time the
16 IFU is created, so it will always evolve.

17 BY MR. SLATER:

18 Q. The information Ethicon had about the
19 complications and risks from the Prolift® evolved
20 over the years. Right?

21 A. Yes.

22 Q. That evolution was actually fairly
23 significant as more and more procedures were done
24 and Ethicon saw more clinical studies. Right?

25 MR. GAGE: Objection.